On July 30, Regeneron Pharmaceuticals rose 4.25% in pre-market trading, trading at approximately $725.5 per share, with turnover of approximately $406,600.

The movement was driven by the company's Q2 earnings release before market open, which significantly exceeded Wall Street expectations. Adjusted EPS came in at $14.29, beating the analyst consensus estimate of $10.26 by 39.28% and representing a 10.86% year-over-year increase from $12.89. Revenue reached $4.291 billion, surpassing the market estimate of $3.816 billion. Notably, the company had previously filed with the SEC warning that Q2 EPS would decline by approximately $1, making the actual outperformance even more striking and fueling rapid buying interest.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)